NELSEN ROBERT 4

What Happened

• Robert Nelsen, reported as a 10% owner of Prime Medicine (PRME), was granted a derivative award covering 75,000 shares on 2026-06-05. The filing reports a $0.00 price and a $0 total cash payment — this is a grant of a derivative (described in the filing as an option), not an open‑market purchase or sale. This is a compensation/ownership grant rather than a cash transaction.

Key Details

• Transaction date: 2026-06-05; filing date: 2026-06-08 (filing appears to be within required timing).
• Securities: 75,000 derivative shares (option); reported price $0.00; reported value $0.
• Shares owned after transaction: Not disclosed in the filing.
• Footnote: The option vests in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to Nelsen’s continuous service through the vesting date.
• No indication in the filing of a sale, exercise, cashless exercise, or tax‑withholding event related to this grant.

Context

• This is a derivative grant to a 10% owner (a significant shareholder), which increases potential upside exposure but does not represent an immediate purchase of common stock or cash outlay. Derivative awards typically vest over time and only convert to owned shares if vesting conditions are met and any exercise requirements are satisfied. As reported, there was no immediate sale of shares.